GLP-1 in Aesthetics: Compounding, Sourcing & Legal Status

The FDA's drug shortage designations for semaglutide and tirzepatide—which previously permitted pharmacies to compound these drugs without a brand-name equivalent in stock—have expired or been significantly narrowed. As of mid-2026, neither drug carries a blanket shortage declaration that would automatically authorize compounding. This means that compounding pharmacies must now justify compounding under 503(b) (outsourcing facility) or 503(a) (traditional pharmacy) rules, which require either a patient-specific prescription or a documented, significant supply gap for an FDA-approved product. Many practices that sourced compounded GLP-1 from third-party pharmacies are now operating in a gray zone: the pharmacy may lack clear legal authority to compound, and the practice may face liability for administering a drug of uncertain provenance and potency. Check the FDA's current drug shortage list (fda.gov/drugs/drug-shortages) and confirm with your compounding pharmacy that they hold 503(b) outsourcing facility registration or can document a valid 503(a) compounding justification. If neither applies, you are sourcing an unapproved drug product.

State medical boards and pharmacy boards have begun issuing guidance and enforcement actions against practices offering compounded GLP-1 without clear prescribing authority or medical supervision. Several states have clarified that GLP-1 use for cosmetic weight loss (as opposed to treatment of diabetes or obesity under a physician's care plan) falls outside the scope of practice for many non-physician providers and may violate delegation/supervision rules. Pharmacy boards have also targeted compounding pharmacies that lack documented shortage justification. Enforcement typically begins with a complaint (often from a patient or competitor), followed by an investigation into prescribing records, pharmacy sourcing, and whether the administering provider held appropriate licensure and medical supervision. Penalties range from a cease-and-desist letter to license suspension or revocation. Before offering GLP-1, consult your state medical board (name the specific board) and state pharmacy board to confirm: (1) whether your license permits prescribing or administering GLP-1 for cosmetic purposes, (2) whether physician supervision is required, and (3) whether your compounding pharmacy is registered and has documented authority to compound.

Approved brand products: Novo Nordisk's Saxenda (liraglutide) and Wegovy (semaglutide) are FDA-approved for chronic weight management; Eli Lilly's Mounjaro (tirzepatide) is approved for type 2 diabetes, and Zepbound (tirzepatide) is approved for weight management. These carry full FDA oversight, pharmacovigilance, and liability protection for the manufacturer. Prescribing or administering these requires a valid prescription and appropriate licensure. Compounded products: Compounded semaglutide and tirzepatide are manufactured by 503(b) outsourcing facilities or 503(a) pharmacies. Quality, potency, and sterility are not guaranteed to FDA standards; the practice assumes liability for adverse events. Gray-market and international sources: Some practices source from overseas suppliers or unlicensed compounders. This carries criminal and civil risk. Recommendation: If you wish to offer GLP-1, use only FDA-approved brand products (Saxenda, Wegovy, Zepbound, Mounjaro) prescribed by a licensed provider with appropriate medical oversight. If you source compounded product, verify in writing that the pharmacy holds 503(b) registration or has documented 503(a) compounding authority, and maintain records of that justification. Do not source from overseas or unlicensed suppliers.

Prescribing GLP-1 for cosmetic weight loss is not within the scope of practice for all provider types. Physicians (MDs, DOs) may prescribe GLP-1 for weight management if they have appropriate training and medical judgment. Nurse practitioners and physician assistants may prescribe GLP-1 only if state law permits and they operate under physician supervision or collaboration (requirements vary by state). Nurse injectors, aestheticians, and other non-prescribing providers may not prescribe GLP-1; if they administer it, they must do so under a valid standing order or protocol from a supervising physician, and the physician must have examined the patient and documented medical necessity. Many states require that the supervising physician be on-site or available for consultation. Offering GLP-1 as a cosmetic service (rather than as treatment for a diagnosed metabolic condition) may trigger additional scrutiny: some state boards view this as practicing medicine without a license if the provider lacks prescribing authority. Action: Confirm your state's scope-of-practice rules for your license type. If you are a non-prescriber, obtain a written protocol from a supervising physician that specifies patient selection criteria, dosing, monitoring, and adverse-event reporting. Document that the physician has examined each patient before injection.

GLP-1 use carries real clinical risks: pancreatitis, thyroid C-cell tumors (in animal studies), gastroparesis, dehydration, and acute kidney injury have been reported. Off-label use for cosmetic weight loss—especially in patients without diabetes or obesity—may be viewed as higher-risk by malpractice insurers and state boards. If a patient suffers an adverse event and it emerges that you sourced compounded product of unknown potency, or that you lacked prescribing authority, or that you failed to document informed consent or medical supervision, your liability exposure is severe. Malpractice insurers may deny coverage if the use falls outside your scope of practice. Documentation essentials: (1) Patient medical history, including metabolic disorders, medications, and contraindications; (2) Informed consent that explicitly addresses off-label use, compounding status (if applicable), and known risks; (3) Prescriber's order or standing protocol (if applicable); (4) Product lot number, expiration date, and source (brand name or compounding pharmacy name and 503(b) registration number); (5) Injection site, dose, date, and provider name; (6) Follow-up plan and adverse-event reporting mechanism. Maintain records for at least 7 years. Confirm that your malpractice policy covers GLP-1 administration; if not, seek a rider or alternative coverage.

If you administer GLP-1, you are responsible for monitoring for adverse events and reporting serious events to the FDA (via MedWatch) and to your state medical board (if required by state law). Serious events include pancreatitis, acute kidney injury, severe dehydration, allergic reaction, and any hospitalization. Failure to report can result in board discipline. Additionally, if you use compounded product, you should report any quality or potency issues to the compounding pharmacy and the FDA. Many practices do not have a formal adverse-event tracking system; this is a gap. Implement: (1) A post-injection follow-up protocol (phone call or email at 24–48 hours and 1–2 weeks); (2) A patient-reported adverse-event form or hotline; (3) A log of all adverse events, with dates and outcomes; (4) A process for reporting serious events to MedWatch (fda.gov/medwatch) and your state board within the required timeframe (typically 10–30 days). If you use a compounding pharmacy, share adverse-event reports with them and request that they investigate and report to the FDA if the event may be related to product quality.